Vaginal Microbiome Testing Market

Vaginal Microbiome Testing Market Analysis

The Vaginal Microbiome Testing Market size is estimated at USD 159.99 million in 2025, and is expected to reach USD 250.05 million by 2030, at a CAGR of 9.34% during the forecast period (2025-2030).

Vaginal microbiome testing can help to identify specific bacterial profiles, allowing for tailored treatment plans that address the unique health conditions.The major factors driving the studied market are the growing awareness about Women’s reproductive health, rising incidence of vaginal infections, advancements in genomic technologies,increasing awareness of women’s health, and growing strategic activities by the key players in the market.

The growing awareness about women’s reproductive health increases the demand for vaginal microbiome testing to identify bacterial vaginosis, yeast infections, and other vaginal issues to maintain a healthy reproductive system, which ultimately drives the studied market over the forecast period. For instance, in September 2024, the Vulvar Awareness Campaign, which is focused on HPV-related vulvar and vaginal diseases, was led by the International Society for the Study of Vulvovaginal Disease. Hence, such campaigns increase awareness about vaginal health in women and increase the demand for vaginal microbiome testing in the early detection of the and drive the studied market over the forecast period.

Additionally, the rising demand for precision health is also expected to increase the demand for vaginal microbiome testing, which will ultimately drive the studied market over the forecast period. For instance, in February 2023, Evvy, a femtech startup, reported the launch of the digital platform to fill the gender research gap and provide precision health for women. The Evvy platform offers end-to-end care, including physician-reviewed results and personalized prescription treatment programs integrated with its vaginal health test. Hence, the launch of such platforms increases the accessibility of vaginal microbiome testing for providing personalized treatment, which ultimately drives the studied market over the forecast period.

Furthermore, there is growing awareness of women’s health, which will increase the adoption of vaginal microbiome testing, thus driving the overall market. For instance, the findings from the International Microbiota Observatory in February 2024 revealed that while knowledge of vaginal health is improving, awareness is on the rise and highlighted that 44% of women are aware that bacterial vaginosis is linked to an imbalance in the vaginal microbiota and among women aged 60 and over. This shift in awareness has led to increased utilization of vaginal microbiome diagnostics, which drives the vaginal microbiome testing market.

Additionally, in October 2023, Juno Bio, a femtech startup in United Kingdom focused on improving women's health through vaginal microbiome tests, raised USD 25 million in a seed funding round to accelerate its research and development efforts, expand its team, and bring more vaginal microbiome testing products to market.

Thus, the growing awareness about the women’s reproductive health and increasing awareness for women's health are expected to drive the studied market over the forecast period. However, the high cost of microbiome testing is expected to restrain the studied market over the forecast period.

Vaginal Microbiome Testing Market Trends

Infectious Disease is Expected to Hold Significant Market Share Over the Forecast Period.

A vaginal infection can occur if the natural balance of the microbiome is disrupted or if unhealthy bacteria enter into the vagina. This often leads to changes in the vaginal microbiome environment. The major factors driving the segment growth are the rising prevalence of vaginal infectious diseases and growing strategic activities by key players.

The rising prevalence of vaginal infections, such as bacterial vaginosis, and sexually transmitted diseases, such as chlamydia and gonorrhea, increases the demand for vaginal microbiome testing for the diagnosis of these infections and provides the appropriate treatment, which ultimately drives the studied market over the forecast period.

For instance, according to an article published in the American Society for Microbiology in April 2023, a study of around 429 women with symptoms of vaginitis who were enrolled in a hospital in northern Taiwan with 438 episodes of vaginitis demonstrated that 40% of vaginitis in Taiwan was caused by either trichomoniasis, bacterial vaginosis, vulvovaginal candidiasis, or any combination these infections. Hence, the significant prevalence of vaginal infections is expected to increase the demand for vaginal microbiome testing, which will ultimately drive the studied market over the forecast period.

Furthermore, molecular detection methods, particularly PCR-based assays, are revolutionizing the diagnosis of bacterial vaginosis (BV), offering a more accurate and reliable alternative to traditional methods like nugent scoring.

For instance, according to a study published in the Diagnostic Microbiology and Infectious Disease in February 2024, real-time PCR assays for key bacterial species associated with BV Gardnerella vaginalis, Atopobium vaginae, and Lactobacillus spp. demonstrated excellent diagnostic accuracy when compared to the gold standard Nugent scoring. Real-time PCR was able to correctly identify a significant number of BV-positive cases that Nugent scoring classified as intermediate. This level of accuracy and precision highlights the growing preference for vaginal microbiome diagnostics in clinical settings. As a result, the demand for the molecular diagnostics for infectious diseases segment in the vaginal microbiome testing market is anticipated to surge.

Thus, the increasing prevalence of vaginal infectious diseases and rising adoption of vaginal microbiome testing in the market are expected to drive the studied segment growth over the forecast period.

North America is Expected to Hold the Significant Market Share Over the Forecast Period

The vaginal microbiome testing in North America is driven by factors such as the advanced research infrastructure, rising awareness of women’s health issues, the prevalence of vaginal disorders, growing technological advancements, growing adoption of personalized healthcare, and increasing accessibility and awareness of vaginal microbiome testing.

In the United States, the rising incidence of bacterial vaginosis (BV) among women is poised to fuel substantial growth in the vaginal microbiome testing market. For example, a September 2024 study in the Journal of Reproductive Immunology reported a high prevalence of bacterial vaginosis in the United States. This significant prevalence underscores the urgent demand for enhanced diagnostic solutions to pinpoint BV and its related pathogens accurately. With an increasing number of women addressing vaginal health issues in healthcare settings, the demand for these diagnostic tools is set to surge, propelling the vaginal microbiome testing market in the United States.

The rising technological advancements in vaginal microbiome testing are expected to increase the affordability of these tests and drive the studied market over the forecast period. For instance, in For instance, in March 2023, BD's recent Food Drug and Administration 510(k) clearance for the BD Vaginal Panel on the BD COR System. This PCR-based assay detects organisms responsible for bacterial vaginosis using a single swab and test. The BD COR System allows laboratories to run these high-throughput molecular diagnostics, making it an ideal solution for large-scale testing environments. Such approvals will increase the adoption of molecular diagnostics methods within the vaginal microbiome testing market and will drive the segment’s growth during the forecasted period.

Furthermore, the raising awareness about conditions, the hub aims to improve health outcomes and also fosters a greater demand for accurate and effective BV diagnostics. For instance, an article published in April 2024 highlighted that the Healthy Pregnancy Hub, a key initiative under the Pan-Canadian Women’s Health Coalition, focuses on providing reliable and culturally sensitive information about the safety of medication use during pregnancy. This is particularly relevant for BV, as untreated infections can lead to serious complications for both the mother and the fetus.

With heightened awareness of infectious diseases and their implications for pregnancy, the Healthy Pregnancy Hub is poised to boost demand for effective diagnostic tools, enabling early detection and timely treatment. Furthermore, its commitment to bilingual resources ensures that diverse populations across Canada have access to vital information about vaginal infectious diseases, enhancing understanding and promoting proactive health measures and thereby driving the market’s growth in the country.

Hence, the rising technological advancements in vaginal microbiome testing and raising awareness for vaginal microbiomes are expected to increase the demand for vaginal microbiome tests and services, which will ultimately drive the studied market over the forecast period.

Vaginal Microbiome Testing Industry Overview

The vaginal microbiome testing market is semiconsolidated due to the presence of a few global and regional players in the field. The major players in the market are adopting various strategic activities such as mergers and collaborations and raising funds for the development of new tests. Some of the key players in the market are Biomérieux, Hologic, Inc., Evvy, Juno Bio, and Thermo Fisher Scientific Inc.

Vaginal Microbiome Testing Market Leaders

Vaginal Microbiome Testing Market News

• May 2024: Seed Health unveiled VS-01, a groundbreaking vaginal microbiome solution set to transform vaginal care. VS-01 is a clinically validated multi-strain probiotic and prebiotic designed to optimize the vaginal microbiome and maintain a balanced vaginal pH.
• February 2024: MyMicrobiome launched the Vulvo-Vaginal Standard 25.10 testing, a thorough evaluation aimed at ensuring the safety of products on the vulva and vagina's microbiome. This standard encompasses microorganisms found both inside the vagina and in external areas, including the labia. Such launches can contribute to increasing the adoption of vaginal microbiome testing and thereby impact the market's growth.